< >

HyperAcute™ Immunotherapy

NewLink Genetics has multiple HyperAcute™ immunotherapies currently under development in a variety of tumors

Phase 3 Trial in Pancreatic Cancer

Now enrolling patients with borderline resectable or locally advanced unresectable pancreatic cancer

Phase 2b/3 Trial in Lung Cancer

Now enrolling patients with progressive or relapsed non-small cell lung cancer (NSCLC)

Investor Relations

Keep up with the latest news and presentations
NewLink Genetics Announces Exclusive Worldwide Licensing Agreement for Development of NLG919, an IDO Inhibitor in Phase 1, and Research Collaboration for the Discovery of Next Generation IDO/TDO Inhibitors
October 20, 2014

NewLink Genetics Corporation Announces Appointment of New Executive Vice President and Chief Financial Officer
October 01, 2014

Read more news
ANNOUNCEMENTS
©2013 New Link Genetics, Inc. All rights reserved.
Site Map       Terms & Conditions       Privacy Policy       Contact Us